# A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.

> **NCT07363707** · PHASE4 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 108 (actual)

## Conditions studied

- NAFLD (Nonalcoholic Fatty Liver Disease)

## Interventions

- **DRUG:** Dapagliflozin + Metformin
- **DRUG:** Empa

## Key facts

- **NCT ID:** NCT07363707
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2023-08-27
- **Final completion:** 2024-03-01
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363707, "A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07363707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*